Rogier C. Buijsman

Netherlands Translational Research Center BV develops small molecule drug leads and preclinical candidates for cancer, autoimmune and Parkinson diseases. Its product NFK GreenScreen plays an important role in immune modulation and neurodegenerative disease. The firm also offers Oncolines, OncolinesProfiler, SynergyFinder, ResidenceTimer and EntropySelect services. The company was founded by Guido J. R. Zaman and Rogier C. Buijsman in June 2011 and is headquartered in Oss, the Netherlands.

Netherlands Translational Research Center BV develops small molecule drug leads and preclinical candidates for cancer, autoimmune and Parkinson diseases. Its product NFK GreenScreen plays an important role in immune modulation and neurodegenerative disease. The firm also offers Oncolines, OncolinesProfiler, SynergyFinder, ResidenceTimer and EntropySelect services. The company was founded by Guido J. R. Zaman and Rogier C. Buijsman in June 2011 and is headquartered in Oss, the Netherlands.

Netherlands Translational Research Center BV develops small molecule drug leads and preclinical candidates for cancer, autoimmune and Parkinson diseases. Its product NFK GreenScreen plays an important role in immune modulation and neurodegenerative disease. The firm also offers Oncolines, OncolinesProfiler, SynergyFinder, ResidenceTimer and EntropySelect services. The company was founded by Guido J. R. Zaman and Rogier C. Buijsman in June 2011 and is headquartered in Oss, the Netherlands.

Netherlands Translational Research Center BV develops small molecule drug leads and preclinical candidates for cancer, autoimmune and Parkinson diseases. Its product NFK GreenScreen plays an important role in immune modulation and neurodegenerative disease. The firm also offers Oncolines, OncolinesProfiler, SynergyFinder, ResidenceTimer and EntropySelect services. The company was founded by Guido J. R. Zaman and Rogier C. Buijsman in June 2011 and is headquartered in Oss, the Netherlands.